Cargando…
Cardiovascular magnetic resonance imaging characteristics in patients with methamphetamine-associated cardiomyopathy
BACKGROUND: Methamphetamine-associated cardiomyopathy (MA-CMP) is an increasingly recognised aetiology of cardiomyopathy. Cardiovascular magnetic resonance (CMR) is a specialised cardiac imaging modality commonly used in assessment of cardiomyopathy. We aimed to identify specific CMR features associ...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9713956/ https://www.ncbi.nlm.nih.gov/pubmed/36451214 http://dx.doi.org/10.1186/s12968-022-00898-6 |
_version_ | 1784842120623816704 |
---|---|
author | Stokes, Michael B. Thoi, Fiona Scherer, Daniel J. Win, Kyi T. H. Kaye, David M. Teo, Karen S. Sanders, Prashanthan |
author_facet | Stokes, Michael B. Thoi, Fiona Scherer, Daniel J. Win, Kyi T. H. Kaye, David M. Teo, Karen S. Sanders, Prashanthan |
author_sort | Stokes, Michael B. |
collection | PubMed |
description | BACKGROUND: Methamphetamine-associated cardiomyopathy (MA-CMP) is an increasingly recognised aetiology of cardiomyopathy. Cardiovascular magnetic resonance (CMR) is a specialised cardiac imaging modality commonly used in assessment of cardiomyopathy. We aimed to identify specific CMR features associated with MA-CMP. METHODS: A retrospective cohort study of CMR scans was performed in a single centre between January 2015 and December 2020. Thirty patients with MA-CMP who had undergone CMR were identified. MA-CMP was defined as those with a history of significant methamphetamine use hospitalised with acute decompensated heart failure (other causes of cardiomyopathy excluded). A retrospective analysis of index admission CMRs was performed. All studies were performed on a 1.5 T CMR scanner. RESULTS: The mean age of MA-CMP patients was 43.7 ± 7.5 years, and 86.7% were male. The mean left ventricular (LV) volume obtained in this cohort was consistent with severe LV dilatation (LV end-diastolic volume (334 ± 99 ml); LV end-systolic volume: 269 ± 98 ml), whilst the right ventricular (RV) volume indicated moderate-to-severe dilatation (RV end-diastolic volume: 272 ± 91 ml; RV end-systolic volume: 173 ± 82 ml). Mean LV ejection fraction (20.9 ± 9.2%) indicated severe LV dysfunction, with moderate-to-severe RV dysfunction also detected (RV ejection fraction: 29.4 ± 13.4%). 22 patients (73.3%) had myocardial late gadolinium enhancement (LGE), of which 59.1% were located in the mid-wall, with all of these involving the interventricular septum. 22.7% displayed localised regions of sub-endocardial LGE in a variety of locations, and 18.2% had transmural regions of LGE that were located in the inferior and inferolateral segments. 6 patients (20%) had intracardiac thrombus (4 LV, 2 both LV and RV). CONCLUSION: MA-CMP was associated with severe biventricular dilatation and dysfunction, with a high prevalence of intraventricular thrombus. This cohort study highlights that MA-CMP patients have a high prevalence of CMR findings. |
format | Online Article Text |
id | pubmed-9713956 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-97139562022-12-02 Cardiovascular magnetic resonance imaging characteristics in patients with methamphetamine-associated cardiomyopathy Stokes, Michael B. Thoi, Fiona Scherer, Daniel J. Win, Kyi T. H. Kaye, David M. Teo, Karen S. Sanders, Prashanthan J Cardiovasc Magn Reson Research BACKGROUND: Methamphetamine-associated cardiomyopathy (MA-CMP) is an increasingly recognised aetiology of cardiomyopathy. Cardiovascular magnetic resonance (CMR) is a specialised cardiac imaging modality commonly used in assessment of cardiomyopathy. We aimed to identify specific CMR features associated with MA-CMP. METHODS: A retrospective cohort study of CMR scans was performed in a single centre between January 2015 and December 2020. Thirty patients with MA-CMP who had undergone CMR were identified. MA-CMP was defined as those with a history of significant methamphetamine use hospitalised with acute decompensated heart failure (other causes of cardiomyopathy excluded). A retrospective analysis of index admission CMRs was performed. All studies were performed on a 1.5 T CMR scanner. RESULTS: The mean age of MA-CMP patients was 43.7 ± 7.5 years, and 86.7% were male. The mean left ventricular (LV) volume obtained in this cohort was consistent with severe LV dilatation (LV end-diastolic volume (334 ± 99 ml); LV end-systolic volume: 269 ± 98 ml), whilst the right ventricular (RV) volume indicated moderate-to-severe dilatation (RV end-diastolic volume: 272 ± 91 ml; RV end-systolic volume: 173 ± 82 ml). Mean LV ejection fraction (20.9 ± 9.2%) indicated severe LV dysfunction, with moderate-to-severe RV dysfunction also detected (RV ejection fraction: 29.4 ± 13.4%). 22 patients (73.3%) had myocardial late gadolinium enhancement (LGE), of which 59.1% were located in the mid-wall, with all of these involving the interventricular septum. 22.7% displayed localised regions of sub-endocardial LGE in a variety of locations, and 18.2% had transmural regions of LGE that were located in the inferior and inferolateral segments. 6 patients (20%) had intracardiac thrombus (4 LV, 2 both LV and RV). CONCLUSION: MA-CMP was associated with severe biventricular dilatation and dysfunction, with a high prevalence of intraventricular thrombus. This cohort study highlights that MA-CMP patients have a high prevalence of CMR findings. BioMed Central 2022-12-01 /pmc/articles/PMC9713956/ /pubmed/36451214 http://dx.doi.org/10.1186/s12968-022-00898-6 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Stokes, Michael B. Thoi, Fiona Scherer, Daniel J. Win, Kyi T. H. Kaye, David M. Teo, Karen S. Sanders, Prashanthan Cardiovascular magnetic resonance imaging characteristics in patients with methamphetamine-associated cardiomyopathy |
title | Cardiovascular magnetic resonance imaging characteristics in patients with methamphetamine-associated cardiomyopathy |
title_full | Cardiovascular magnetic resonance imaging characteristics in patients with methamphetamine-associated cardiomyopathy |
title_fullStr | Cardiovascular magnetic resonance imaging characteristics in patients with methamphetamine-associated cardiomyopathy |
title_full_unstemmed | Cardiovascular magnetic resonance imaging characteristics in patients with methamphetamine-associated cardiomyopathy |
title_short | Cardiovascular magnetic resonance imaging characteristics in patients with methamphetamine-associated cardiomyopathy |
title_sort | cardiovascular magnetic resonance imaging characteristics in patients with methamphetamine-associated cardiomyopathy |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9713956/ https://www.ncbi.nlm.nih.gov/pubmed/36451214 http://dx.doi.org/10.1186/s12968-022-00898-6 |
work_keys_str_mv | AT stokesmichaelb cardiovascularmagneticresonanceimagingcharacteristicsinpatientswithmethamphetamineassociatedcardiomyopathy AT thoifiona cardiovascularmagneticresonanceimagingcharacteristicsinpatientswithmethamphetamineassociatedcardiomyopathy AT schererdanielj cardiovascularmagneticresonanceimagingcharacteristicsinpatientswithmethamphetamineassociatedcardiomyopathy AT winkyith cardiovascularmagneticresonanceimagingcharacteristicsinpatientswithmethamphetamineassociatedcardiomyopathy AT kayedavidm cardiovascularmagneticresonanceimagingcharacteristicsinpatientswithmethamphetamineassociatedcardiomyopathy AT teokarens cardiovascularmagneticresonanceimagingcharacteristicsinpatientswithmethamphetamineassociatedcardiomyopathy AT sandersprashanthan cardiovascularmagneticresonanceimagingcharacteristicsinpatientswithmethamphetamineassociatedcardiomyopathy |